2022 Guide to Patient Support Services

Incyte

IncyteCARES: Connecting to Access, Reimbursement, Education, and Support

855-452-5234

IncyteCARES (Connecting to Access, Reimbursement, Education, and Support) assists eligible patients and healthcare providers in obtaining access to its oncology drugs Jakafi or Pemazyre and connects them with continuing support and resources (Table).

IncyteCARES Services

IncyteCARES provides several services for patients who are using Jakafi or Pemazyre, including information about reimbursement support, financial assistance options, educational support, and referrals to patient advocacy organizations.

Jakafi Savings Program and Pemazyre Copay/Coinsurance Program

Through these IncyteCARES programs, eligible patients can receive Jakafi for as little as $0 per month or Pemazyre for a $0 copay, subject to monthly and annual limits.

Patients are eligible if they have commercial or private prescription drug coverage. Patients insured under federal or state government prescription drug programs, including Medicare Part D, Medicare Advantage, Medicaid, or TRICARE, are not eligible. Patients without prescription drug coverage are also not eligible. Patients must be a resident of the United States or a US territory and have a valid prescription for an Incyte medication for an FDA-approved or compendia-recognized use.

To learn more, call IncyteCARES for Jakafi at 855-452-5234, Monday-Friday, 8 am–8 pm ET. For information regarding support for Pemazyre, which is dispensed by Biologics by McKesson specialty pharmacy, call IncyteCARES at 866-708-8806, Monday-Friday, 8 am–8 pm ET. Biologics will work with you and your patient to provide therapeutic expertise and individualized support.

IncyteCARES Patient Assistance Program

Patients without prescription drug coverage for Jakafi or Pemazyre, or those who have been denied claims for treatment with Jakafi or Pemazyre, may be eligible to receive their medication free of charge through the IncyteCARES Patient Assistance Program.

To qualify, patients must:

  • Be confirmed as eligible for and enrolled in IncyteCARES for Jakafi or Pemazyre
  • Be a resident of the United States or Puerto Rico (for Jakafi) or US territories (for Pemazyre)
  • Have a valid prescription for Jakafi or Pemazyre for an FDA-approved or compendia-recognized use.

If underinsured or if uninsured with no coverage, patients may qualify for the Patient Assistance Program if they meet certain household size and annual income criteria or have exhausted their benefits and cannot afford their medication or out-of-pocket expenses. Patients insured under Medicare Part D may qualify by meeting additional criteria and program requirements.

IncyteCARES Temporary Access Program

Eligible patients may be able to receive a free short-term supply of Jakafi or Pemazyre. If a patient’s prescription drug insurer requires more than a 3-day wait for determining coverage approval, a free 30-day supply of the prescribed Incyte medication in the meantime may be provided. No purchase contingencies or other obligations apply.

To qualify, patients must:

  • Be confirmed as eligible for and enrolled in IncyteCARES
  • Have commercial prescription drug coverage or a healthcare exchange plan. Patients insured under federal or state government prescription drug programs—including Medicare Part D, Medicare Advantage, Medicaid, or TRICARE—are not eligible. Patients without prescription drug coverage are also not eligible
  • Be a resident of the United States or Puerto Rico (for Jakafi) or US territories (for Pemazyre)
  • Have a valid prescription for an Incyte medication for an FDA-approved use
  • Provide proof of the coverage delay.

Nonprofit or Other Support Organizations

Patients who do not qualify for the IncyteCARES programs, including those patients covered by any type of insurance or those without insurance, may be eligible for help with medication costs, treatment-related travel, and other expenses. Referrals to organizations or independent foundations that may offer help can be provided. Eligibility and availability of these assistance programs are determined by the individual organizations.

TABLE Incyte Oncology Drugs

Drugs
Indications
Patient support programs

Drug
Jakafi (ruxolitinib) tablets
Indications
Treatment of polycythemia vera in adults who have had an inadequate response to, or are intolerant of, hydroxyurea; treatment of intermediate- or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF in adults; and treatment of steroid-refractory acute graft-versus-host disease in patients aged ≥12 years
Patient support programs

Drug
Pemazyre (pemigatinib) tablets
Indications
Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement, as detected by an FDA-approved test
Patient support programs

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"
Comments
(Optional)